Royalty Pharma (RPRX) Minority Interest (2019 - 2026)

Royalty Pharma has disclosed Minority Interest across 8 years of filings, most recently posting $3.0 billion for Q2 2026.

• In Q2 2026, Minority Interest fell 6.4% year-over-year to $3.0 billion; the TTM figure through Jun 2026 stood at $3.0 billion (down 6.4% YoY), while the FY2025 annual figure was $3.2 billion, down 4.65% from the prior year.
• Minority Interest came in at $3.0 billion for Q2 2026 at Royalty Pharma, down from $3.0 billion in the prior quarter.
• In the past five years, Minority Interest ranged from a high of $4.4 billion in Q2 2022 to a low of $3.0 billion in Q2 2026.
• Average Minority Interest over 5 years is $3.5 billion, with a median of $3.4 billion recorded in 2024.
• Year-over-year, Minority Interest decreased 19.38% in 2023 and decreased 1.67% in 2026.
• Over 5 years, Minority Interest stood at $3.9 billion in 2022, then dropped by 8.71% to $3.6 billion in 2023, then retreated by 4.55% to $3.4 billion in 2024, then slipped by 4.65% to $3.2 billion in 2025, then dropped by 8.8% to $3.0 billion in 2026.
• Per Business Quant data, the three most recent Minority Interest figures were $3.0 billion in Q2 2026, $3.0 billion in Q1 2026, and $3.2 billion in Q4 2025.